Strike Pharma are aiming to use their Adaptable Drug Affinity Conjugate (ADACTM) technology to enable development of individualized immunotherapeutic treatments based on the genetic profile of each patient’s tumor, to increase efficiency and decrease dosage level, ultimately reducing the risk of side effects.
Strike Pharma joined NOME in 2024.